Treatment Effects of Bifidobacterium Quadruple Viable Tablets Combined With Quadruple Therapy on Helicobacter Pylori -Infected Peptic Ulcer in Children
Restricted accessResearch articleFirst published online January, 2025
Treatment Effects of Bifidobacterium Quadruple Viable Tablets Combined With Quadruple Therapy on Helicobacter Pylori -Infected Peptic Ulcer in Children
This study aimed to investigate the treatment effects of Bifidobacterium quadruple viable tablets combined with quadruple therapy on Helicobacter pylori (Hp)-infected peptic ulcer in children. A total of 124 children with Hp-infected peptic ulcers were allocated into 2 treatment groups: control group (quadruple therapy) and observation group (quadruple therapy plus Bifidobacterium quadruple viable tablets). After treatment, the 2 groups were compared in terms of ulcer healing, serum inflammatory cytokines, Hp elimination, gastrointestinal hormones, and intestinal flora. After treatment, the children in the observation group possessed lower serum interleukin-6, tumor necrosis factor α, procalcitonin, C-reactive protein, gastrin, and motilin levels, and higher ulcer healing rate, Hp clearance rate, somatostatin levels and bifidobacterium and lactobacillus versus those in the control group. Bifidobacterium quadruple viable tablets combined with quadruple therapy has good efficacy in Hp-associated peptic ulcer disease.
LiangTYDengRMLiXXuXChenG.The role of nitric oxide in peptic ulcer: a narrative review. Med Gas Res. 2021;11(1):42-45.
2.
KavittRTLipowskaAMAnyane-YeboaAGralnekIM.Diagnosis and treatment of peptic ulcer disease. Am J Med. 2019;132(4):447-456.
3.
SalehMSohrabpourAAMehrabiMRSeyhounIVaeziAA.Therapeutic approach of adipose-derived mesenchymal stem cells in refractory peptic ulcer. Stem Cell Res Ther. 2021;12(1):515.
4.
SerafimCArarunaMEJuniorEADinizMHiruma-LimaCBatistaL.A review of the role of flavonoids in peptic ulcer (2010-2020). Molecules. 2020;25(22):5431.
5.
de BritoBBda SilvaFAFSoaresAS, et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol. 2019;25(37):5578-5589.
6.
Flores-TreviñoSMendoza-OlazaránSBocanegra-IbariasPMaldonado-GarzaHJGarza-GonzálezE.Helicobacter pylori drug resistance: therapy changes and challenges. Expert Rev Gastroenterol Hepatol. 2018;12(8):819-827.
7.
SunYZhangJ.Helicobacter pylori recrudescence and its influencing factors. J Cell Mol Med. 2019;23(12):7919-7925.
8.
Tshibangu-KabambaEYamaokaY.Helicobacter pylori infection and antibiotic resistance—from biology to clinical implications. Nat Rev Gastroenterol Hepatol. 2021;18(9):613-629.
9.
AssefaBTadesseAAbayZ, et al. Peptic ulcer disease among dyspeptic patients at endoscopy unit, University of Gondar hospital, Northwest Ethiopia. BMC Gastroenterol. 2022;22(1):164.
10.
SawadaA.[Peptic ulcer in children]. Nihon Rinsho. 2004;62(3):546-550.
11.
EdwardsMJKollenbergSJBrandtML, et al. Surgery for peptic ulcer disease in children in the post-histamine2-blocker era. J Pediatr Surg. 2005;40(5):850-854.
12.
Abd-ElsalamSKobtanAEl-KallaF, et al. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: a single center experience. Medicine (Baltimore). 2016;95(24):e3879.
13.
ShehataMATalaatRSolimanSElmesseriHSolimanSAbd-ElsalamS.Randomized controlled study of a novel triple nitazoxanide (NTZ)-containing therapeutic regimen versus the traditional regimen for eradication of Helicobacter pylori infection. Helicobacter. 2017;22(5):e12395.
14.
BaiTZengHLongY, et al. The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial. Trials. 2020;21(1):597.
15.
HeCXieYZhuY, et al. Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: a multicenter randomized double-blind placebo-controlled trial. Front Immunol. 2022;13:1033063.
16.
FashnerJGituAC.Diagnosis and treatment of peptic ulcer disease and H. pylori infection. Am Fam Physician. 2015;91(4):236-242.
17.
CheyWDLeontiadisGIHowdenCWMossSF.ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212-239.
18.
JiangXXuCLiuBChenPXuQZhangL.Efficacy and safety of bifidobacterium quadruple viable tablets in the treatment of Helicobacter pylori-infected peptic ulcer or gastritis patients: a systematic review and meta-analysis. BMC Infect Dis. 2023;23(1):313.
19.
PericoLLEmilio-SilvaMTOharaR, et al. Systematic analysis of monoterpenes: advances and challenges in the treatment of peptic ulcer diseases. Biomolecules. 2020;10(2):265.
20.
ArdalaniHHadipanahASahebkarA.Medicinal plants in the treatment of peptic ulcer disease: a review. Mini Rev Med Chem. 2020;20(8):662-702.
21.
FitzGeraldRSmithSM.An overview of Helicobacter pylori infection. Methods Mol Biol. 2021;2283:1-14.
22.
MilicLKaramarkovicAPopadicD, et al. Altered cytokine expression in Helicobacter pylori infected patients with bleeding duodenal ulcer. BMC Res Notes. 2019;12(1):278.
23.
AlmasyanRJafariPFarjanikishGNoorbazarganH.Metabiotic extracted from Bifidobacterium bifidum modulates antioxidant capacity and inflammatory responses during peptic ulcer healing in male wistar rats: a preliminary study. Iran J Microbiol. 2023;15(1):102-110.
24.
FengLYYaoXXJiangSL.Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial. World J Gastroenterol. 2005;11(7):1083-1086.
25.
VeselovskyVADyachkovaMSMenyayloEA, et al. Gene networks underlying the resistance of bifidobacterium longum to inflammatory factors. Front Immunol. 2020;11:595877.
26.
NyssenOPPerez-AisaACastro-FernandezM, et al. European Registry on Helicobacter pylori management: single-capsule bismuth quadruple therapy is effective in real-world clinical practice. United European Gastroenterol J. 2021;9(1):38-46.
27.
HeCPengCWangH, et al. The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults. Helicobacter. 2019;24(4):e12590.
28.
ZhouYLiT.Effects of quadruple therapy combined with probiotics on Helicobacter pylori-related peptic ulcer. Comput Math Methods Med. 2022;2022:1221190.
